See more : Duke Energy Corporation (DUK-PA) Income Statement Analysis – Financial Results
Complete financial analysis of Edesa Biotech, Inc. (EDSA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Edesa Biotech, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- 890 5th Avenue Partners, Inc. (ENFAW) Income Statement Analysis – Financial Results
- Otco International Limited (OTCO.BO) Income Statement Analysis – Financial Results
- Vector Acquisition Corporation (VACQ) Income Statement Analysis – Financial Results
- Nova Royalty Corp. (NOVR.V) Income Statement Analysis – Financial Results
- YHN Acquisition I Limited Unit (YHNAU) Income Statement Analysis – Financial Results
Edesa Biotech, Inc. (EDSA)
About Edesa Biotech, Inc.
Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 328.80K | 410.87K | 211.85K | 228.29K | 1.27M | 758.69K | 372.13K | 545.47K | 286.05K | 697.19K | 854.84K | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 183.47K | 118.19K | 118.79K | 17.60K | 101.29K | 445.32K | 534.45K | 1.13M | 840.25K | 760.26K | 576.53K | 436.40K | 1.01M | 386.09K | 0.00 | 0.00 |
| Gross Profit | 0.00 | -183.47K | -118.19K | -118.79K | 311.20K | 309.58K | -233.47K | -306.17K | 143.86K | -81.56K | -388.13K | -31.06K | -150.35K | -311.90K | 468.75K | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 94.65% | 75.35% | -110.21% | -134.11% | 11.31% | -10.75% | -104.30% | -5.69% | -52.56% | -44.74% | 54.83% | 0.00% | 0.00% |
| Research & Development | 2.88M | 4.79M | 13.34M | 17.95M | 3.33M | 1.10M | 2.09M | 1.97M | 1.73M | 1.03M | 2.46M | 1.45M | 1.83M | 906.52K | 352.78K | 0.00 | 0.00 |
| General & Administrative | 4.13M | 4.43M | 5.04M | 5.73M | 3.38M | 2.05M | 2.76M | 2.94M | 3.32M | 3.23M | 2.87M | 2.24M | 4.43M | 5.84M | 1.15M | 78.50K | 0.00 |
| Selling & Marketing | 0.00 | -183.47K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 4.13M | 4.24M | 5.04M | 5.73M | 3.38M | 2.05M | 2.76M | 2.94M | 3.32M | 3.23M | 2.87M | 2.24M | 4.43M | 5.84M | 1.15M | 78.50K | 0.00 |
| Other Expenses | 0.00 | 0.00 | -780.26K | -10.34M | 37.41K | 0.00 | 0.00 | 0.00 | 24.63K | 0.00 | 0.00 | 0.00 | 112.14K | 87.33K | 30.37K | 0.00 | 0.00 |
| Operating Expenses | 7.01M | 9.22M | 17.59M | 13.34M | 6.71M | 3.14M | 4.84M | 4.92M | 5.05M | 4.26M | 5.33M | 3.65M | 6.37M | 6.83M | 1.53M | 78.50K | 0.00 |
| Cost & Expenses | 7.01M | 9.22M | 17.59M | 13.34M | 6.73M | 3.24M | 5.29M | 5.45M | 6.18M | 5.10M | 6.09M | 4.22M | 6.81M | 7.84M | 1.92M | 78.50K | 0.00 |
| Interest Income | 153.50K | 289.85K | 63.52 | 11.17K | 37.78K | 56.84K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.99K | 4.88K | 11.30K | 2.80K | 4.64K | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.73K | 58.00 | 0.00 |
| Depreciation & Amortization | 186.05K | 183.47K | 118.19K | 118.79K | 57.56K | 6.37K | 188.37K | 179.32K | 149.57K | 159.52K | 158.31K | 124.83K | 112.14K | 87.33K | 13.27K | 4.70K | 0.00 |
| EBITDA | -6.13M | -8.19M | -17.43M | -13.22M | -6.35M | -2.83M | -4.85M | -4.85M | -4.87M | -2.65M | -8.25M | -3.72M | -6.43M | -3.51M | -761.82K | -64.65K | 0.00 |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -1,946.72% | -687.79% | -2,327.12% | -2,295.32% | -363.58% | -752.80% | -770.26% | 1,404.04% | -2,703.14% | -1,010.13% | -122.75% | 0.00% | 0.00% |
| Operating Income | -7.01M | -9.22M | -18.37M | -23.68M | -6.40M | -2.83M | -5.08M | -5.22M | -4.91M | -4.34M | -5.72M | -3.68M | -6.52M | -7.10M | -1.07M | -78.56K | 0.00 |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -1,946.72% | -689.30% | -2,397.11% | -2,288.59% | -385.97% | -571.85% | -1,536.69% | -674.37% | -2,280.23% | -1,018.37% | -124.63% | 0.00% | 0.00% |
| Total Other Income/Expenses | 845.50K | 849.14K | 822.67K | 10.34M | 37.41K | -309.45K | 40.10K | 194.70K | -110.52K | 1.53M | -2.78M | -11.21M | 1.37M | 3.50M | 477.02K | 4.64K | 0.00 |
| Income Before Tax | -6.17M | -8.37M | -17.55M | -13.34M | -6.36M | -2.78M | -5.04M | -5.03M | -5.02M | -2.81M | -8.41M | -14.89M | -5.20M | -7.09M | -588.37K | -73.92K | 0.00 |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -1,935.34% | -675.82% | -2,378.18% | -2,203.30% | -394.66% | -369.88% | -2,260.58% | -2,728.98% | -1,816.40% | -1,016.27% | -68.83% | 0.00% | 0.00% |
| Income Tax Expense | 800.00 | 800.00 | 800.00 | 800.00 | 800.00 | -55.40K | 800.00 | 800.00 | 7.20K | 36.80K | 27.20K | 800.00 | 800.00 | 800.00 | 1.60K | 0.00 | 0.00 |
| Net Income | -6.17M | -8.37M | -17.55M | -13.34M | -6.36M | -2.72M | -5.04M | -5.03M | -5.03M | -2.84M | -8.44M | -14.89M | -5.20M | -7.09M | -589.97K | -73.92K | 0.00 |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -1,935.59% | -662.33% | -2,378.56% | -2,203.65% | -395.23% | -374.73% | -2,267.88% | -2,729.12% | -1,816.68% | -1,016.39% | -69.02% | 0.00% | 0.00% |
| EPS | -1.93 | -2.93 | -8.37 | -7.74 | -5.18 | -4.15 | -10.54 | -218.72 | -23.92 | -15.01 | -46.75 | -121.14 | -49.86 | -78.14 | -15.88 | -7.67 | 0.00 |
| EPS Diluted | -1.93 | -2.93 | -8.37 | -7.73 | -5.18 | -4.15 | -10.54 | -211.28 | -23.92 | -15.01 | -46.75 | -121.14 | -49.86 | -78.14 | -15.88 | -7.67 | 0.00 |
| Weighted Avg Shares Out | 3.20M | 2.86M | 2.10M | 1.73M | 1.23M | 655.00K | 478.23K | 23.00K | 210.15K | 189.45K | 180.54K | 122.89K | 104.23K | 90.68K | 37.14K | 9.63K | 9.96K |
| Weighted Avg Shares Out (Dil) | 3.20M | 2.86M | 2.10M | 1.73M | 1.23M | 655.32K | 478.23K | 23.81K | 210.15K | 189.45K | 180.54K | 122.89K | 104.23K | 90.68K | 37.14K | 9.63K | 9.96K |
Edesa Biotech Reaches Enrollment Milestone in COVID Study
TORONTO, ON / ACCESSWIRE / March 15, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that it has completed enrollment of more than 50% of the patients planned for the...
Edesa Biotech Completes Enrollment for Interim Clinical Study Milestone
TORONTO, ON / ACCESSWIRE / March 9, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that it has completed enrollment of the first cohort of a Phase 2b clinical study...
Edesa Biotech Announces Closing of $10 Million Bought Deal Offering of Common Shares
TORONTO, ON / ACCESSWIRE / March 2, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced the closing of its previously announced underwritten public offering of 1,562,500 common shares of Edesa,...
EDSA Stock Price Increases Over 77% Pre-Market: Why It Happened
The stock price of Edesa Biotech Inc (NASDAQ: EDSA) increased by over 77% pre-market. This is why it happened.
Edesa Biotech Expands COVID-19 Clinical Study to Colombia
TORONTO, ON / ACCESSWIRE / January 11, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, has received approval from the Ministry of Health (INVIMA) in Colombia to expand the clinical trial of its investigational drug EB05 in hospitalized...
Edesa Biotech Issues Letter to Shareholders
TORONTO, ON / ACCESSWIRE / December 30, 2020 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, issued a letter to shareholders from its Chief Executive Officer, Par Nijhawan, providing a review of 2020. Dear Fellow Shareholders, It would be...
Contrasting Edesa Biotech (NASDAQ:EDSA) & Stemline Therapeutics (NASDAQ:STML)
Edesa Biotech (NASDAQ:EDSA) and Stemline Therapeutics (NASDAQ:STML) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, valuation, risk, earnings and institutional ownership....
Edesa Biotech to Develop Novel Treatment for Vitiligo in Collaboration with the National Research Council of Canada
TORONTO, ON / ACCESSWIRE / March 12, 2020 / Edesa Biotech, Inc. (EDSA), a clinical-stage biopharmaceutical company, today announced a collaborative research project with the National Research Council of Canada (NRC) to develop novel immunotherapies for vitiligo as well as...
The Daily Biotech Pulse: Sangamo In Genome-Editing Therapy Deal With Biogen, FDA Nod For Biohaven, Passage Bio IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 27) Global Cord Blood Corp (NYSE: CO ) Cleveland BioLabs, ...
Source: https://incomestatements.info
Category: Stock Reports